Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer

NCT06393166 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Non-Resectable Pancreas Carcinoma

Interventions

DRUG: Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection

Sponsor

Zhejiang Cancer Hospital